Drugs.com - New Drug Approvals

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications

PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for...

Feb 9, 2025 - 21:45
 0
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for...
Read More

Tags:

Previous Article

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treat...

Next Article

Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacafto...

Related Posts

FDA Approves Vimkunya (chikungunya vaccine, recombinant) for Prevention of Disease Caused by Chikungunya Virus

FDA Approves Vimkunya (chikungunya vaccine, recombinant...

Feb 17, 2025  0

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xa...

Feb 24, 2025  0

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen...

Feb 13, 2025  0